AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2766 trials with phase data)• Click on a phase to view related trials
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
- Conditions
- Atypical Hemolytic Uremic Syndrome
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT07218536
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Drug: Mirvetuximab Soravtansine (MIRV)
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1100
- Registration Number
- NCT07218809
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
- Conditions
- Severe Asthma
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 197
- Registration Number
- NCT07218172
- Locations
- 🇮🇱
Research Site, Tel Aviv, Israel
A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT07216131
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
- Conditions
- Large B-cell Lymphoma
- Interventions
- Drug: R-mini-CHOP
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 420
- Registration Number
- NCT07215585
- Locations
- 🇰🇷
Research Site, Seoul, South Korea
- Prev
- 1
- 2
- 3
- 4
- 5
- 668
- Next
News
Trump Administration Secures Deal with EMD Serono to Cut Fertility Drug Prices by Up to 84%
President Trump announced a deal with EMD Serono to reduce fertility medication costs, with Gonal-f available at an 84% discount for IVF patients.
Cellectis Reports Promising Phase 1 Results for Lasme-cel in Relapsed/Refractory B-ALL, Advances to Pivotal Phase 2
Cellectis' allogeneic CAR-T therapy lasme-cel demonstrated a 100% overall response rate in the target Phase 2 population of heavily pretreated relapsed/refractory B-cell acute lymphoblastic leukemia patients.
Takeda Expands AI Drug Discovery Partnership with Nabla Bio in $1B+ Deal
Takeda Pharmaceutical has signed a second multi-year AI partnership with Nabla Bio, potentially worth over $1 billion including milestone payments, to accelerate early-stage drug discovery using artificial intelligence.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Ona Therapeutics Appoints ADC Development Veteran Dr. Antoine Yver as Board Chair to Advance Breast Cancer Pipeline
Ona Therapeutics has appointed Dr. Antoine Yver, a veteran with over 35 years of oncology drug development experience, as Chair of its Board of Directors to guide the company's transition to clinical-stage operations.
Innate Pharma Advances Lacutamab Toward Accelerated Approval for Rare T-Cell Lymphomas
Innate Pharma will host an investor event on October 28, 2025, to discuss lacutamab's path to potential accelerated approval in Sézary syndrome based on Phase 2 TELLOMAK trial data.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
Expedition Therapeutics Secures $165 Million Series A to Advance First-in-Class DPP1 Inhibitor for COPD
Expedition Therapeutics closed an oversubscribed $165 million Series A financing co-led by Sofinnova Investments and Novo Holdings to advance EXPD-101, a next-generation DPP1 inhibitor targeting neutrophilic inflammation in COPD.
Arthrosi Raises $153M to Advance Next-Generation Gout Therapy Through Phase III Trials
Arthrosi Therapeutics completed a $153 million Series E funding round led by Prime Eight Capital to advance pozdeutinurad (AR882) through Phase III trials for gout treatment.